1	Estimation of mean pulmonary artery pressure by cardiovascular
2	magnetic resonance four-dimensional flow and compressed sensing
3	
4	Goran Abdula <sup>*1,2</sup> , Pernilla Bergqvist <sup>*1,2</sup> , Jenny Castaings <sup>1,2</sup> , Alexander Fyrdahl <sup>1,2</sup> ,
5	Daniel Giese <sup>3</sup> , Ning Jin <sup>4</sup> , Frederik Testud <sup>5</sup> , Peder Sörensson <sup>1,6</sup> , Andreas Sigfridsson <sup>1,2</sup> ,
6	Martin Ugander <sup>§1,2,7,8</sup> , David Marlevi <sup>§1,9,#</sup>
7	
8 9 10 11 12 13 14 15 16 17 18	<ul> <li><sup>1</sup>Dept. of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden</li> <li><sup>2</sup>Dept. of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden</li> <li><sup>3</sup>Magnetic Resonance, Siemens Healthcare, GmbH, Erlangen, Germany</li> <li><sup>4</sup>Cardiovascular MR R&amp;D, Siemens Medical Solutions USA, Inc, Cleveland, OH, USA</li> <li><sup>5</sup>Siemens Healthcare AB, Malmö, Sweden</li> <li><sup>6</sup>Dept. of Cardiology, Karolinska University Hospital, Stockholm, Sweden</li> <li><sup>7</sup>Kolling Institute, Royal North Shore Hospital, St Leonards, Sydney, Australia</li> <li><sup>8</sup>University of Sydney, Sydney, Australia</li> <li><sup>9</sup>Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA</li> </ul>
19	* denotes equal contribution as first author
20	§ denotes equal contribution as last author
21 22	# denotes corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 23 Abstract

24 **Background**: Four-dimensional (4D) phase-contrast cardiovascular magnetic resonance 25 (CMR) allows for precise non-invasive estimation of mean pulmonary artery pressure 26 (mPAP) by estimating the duration of pathological vortex persistence in the main pulmonary 27 artery. This has previously been achieved with compressed sensing acceleration of a multiple 28 two-dimensional (CS-M2D) flow sequence, but acquisition using a true time-resolved 3D 29 excitation (CS-4D) offers theoretical advantages including spatiotemporal coherence. This 30 study aimed to validate a state-of-the-art CS-4D sequence with a previously utilized CS-M2D 31 sequence for estimating mPAP, and compare both to right heart catheterization (RHC). 32 **Methods**: The study included patients clinically referred for CMR (n=45), of which a 33 subgroup (n=20) had prior mPAP of >16 mmHg confirmed by RHC. CMR was performed at 34 1.5T using CS-M2D and CS-4D sequences covering the main pulmonary artery. mPAP was 35 estimated using a previously published linear relationship between vortex duration and 36 mPAP. Agreement between CS-M2D and CS-4D estimates was quantified, including analysis 37 of intra- and interobserver variabilities. The diagnostic performance of CS-M2D and CS-4D in predicting mPAP was further compared to gold-standard RHC. Results: CS-M2D and CS-38 39 4D both had average scan durations under 3 minutes (175±36 and 135±34 seconds, 40 respectively). Estimated mPAP by CS-4D and CS-M2D were strongly correlated (R<sup>2</sup>=0.93, p < 0.001), with negligible mean $\pm$ SD bias (0.0 $\pm$ 2.7 mmHg) and good reproducibility. There 41 was excellent agreement with RHC for both CS-M2D ( $R^2=0.92$ , p<0.001, bias 0.6±3.1 42 43 mmHg) and CS-4D (R<sup>2</sup>=0.86, p<0.001, bias 1.1±4.5 mmHg). Conclusions: CS-4D and CS-44 M2D sequences effectively yield interchangeable non-invasive estimations of mPAP, with 45 excellent agreement compared to invasive RHC. They can both be acquired in a scan time 46 applicable to clinical workflow, offering a promising tool for non-invasive mPAP estimation 47 in clinical practice.

### 48 Background

49 4D flow cardiovascular magnetic resonance (CMR) is a non-invasive imaging modality 50 allowing for comprehensive assessment of full-field blood flow along arbitrary flow 51 directions and throughout the entire cardiac cycle (1). The technique has been utilized across 52 a variety of cardiovascular applications (2-5). In the setting of complex multidirectional 53 flows, 4D imaging has shown advantages when compared to traditional 2D phase contrast 54 imaging for both quantifying (6) and visualizing multidirectional flow (7). Moreover, 4D 55 flow enables advanced hemodynamic assessment related to blood flow pattern, such as 56 vorticity and helicity (8). In particular, recent studies have indicated the potential of using 57 volumetric flow quantification using multiple stacked 2D (M2D) phase-contrast imaging with 58 time-resolved three-directional velocity encoding to non-invasively quantify mean pulmonary artery pressure (mPAP) (9, 10) – a key diagnostic marker in diagnosing and prognosticating 59 60 pulmonary hypertension (11). 61 Non-invasive estimation of mPAP depends on identification of vortical flow patterns in the

62 main pulmonary artery, which can be performed in multiple ways. Previous work has utilized 63 M2D imaging whereby 2D slices are stacked together to form a reconstructed 3D volume 64 (12). By comparison, a true 4D acquisition, where the entire volume is acquired using a slab-65 selective excitation scheme and partition encoding, bears a number of theoretical advantages 66 including temporal and spatial coherence, flexibility in acquiring isotropic voxels, and 67 avoiding slice crosstalk. Furthermore, as non-invasive estimation of mPAP requires full 68 coverage of the main pulmonary artery, its clinical adoption has been hindered by a relatively 69 long scan time (13). The implementation of compressed sensing (CS) acceleration now 70 promises acquisition in clinically acceptable scan times (14, 15). However, a direct 71 comparison between M2D and true 4D flow have yet to be performed, and likewise, the 72 accuracy of CS accelerated 4D (CS-4D) flow in detection of vortical flow and thereby

- 73 estimation of mPAP remains unknown. Therefore, the aim of this study was to perform a
- 74 comparison of CS accelerated M2D (CS-M2D) and CS-4D for estimating mPAP, with
- validation against right heart catheterization (RHC) in a sub-cohort of subjects with available
- 76 invasive reference data.
- 77

#### 79 Materials and Methods

# 80 Study Participants

81 The study cohort consisted of two groups. In the first group, thirty-five patients with referral 82 for cardiac magnetic resonance (CMR) imaging who were suspected of having pulmonary 83 hypertension (PH) were included. Reasons for suspected PH were known left ventricular 84 systolic dysfunction or prior echocardiography revealing high systolic pulmonary artery 85 pressure (sPAP). To validate CMR 4D flow estimated mPAP against the invasive reference 86 standard RHC, a second group of 20 patients with mPAP >16 mmHg confirmed by RHC 87 were enrolled. The cutoff of 16 mmHg was chosen since this cutoff represents the lowest 88 pressure required for vortex formation (9). Patients with known contraindications for CMR, 89 arrythmia, pacemaker, other cardiac implants, or valvular prosthesis were excluded. All 90 subjects provided written informed consent, and the study was approved by the Swedish 91 Ethical Review Authority (DNR: 2015/2106-31/1).

#### 92 CMR Imaging

93 CMR images were acquired using either a MAGNETOM Aera 1.5T (n=32) or MAGNETOM 94 Sola 1.5T (n=23) (Siemens Healthineers AG, Erlangen, Germany). Anatomical and 95 functional imaging was performed using breath-held cine imaging with balanced steady-state 96 free precession (bSSFP) in both short and long axis views. Flow imaging of the main 97 pulmonary artery (MPA) was acquired using compressed sensing (CS) accelerated time-98 resolved phase contrast imaging with three-directional velocity encoding, both using multiple 99 2D slices (CS-M2D) and volumetric excitation with partition encoding (CS-4D). The CS-100 M2D approach used 3 averages to reduce respiratory motion artifacts, whereas the CS-4D 101 approach used either a crossed-pair or a pencil-beam respiratory navigator placed over the 102 liver dome. Table 1 shows a summary of imaging parameters used for both scanners.

#### 103 Image Analysis

104 Left ventricular size, function, and mass were evaluated by manual segmentation of end-105 diastolic and end-systolic borders on the bSSFP cine 4-chamber view and short axis stacks 106 using syngo.via (Siemens Healthineers AG, Erlangen, Germany). The basal dimension of the 107 right ventricle (RV) at end-diastole (RVDd) and RV longitudinal function were determined 108 by measuring tricuspid annular plane excursion (TAPSE) in the cine four-chamber view. 109 Scan duration was recorded using a timer in a subgroup of patients, since actual scan duration 110 was not stored in the dicom meta data. 111 For the hemodynamic image analysis, CS-M2D and CS-4D flow data were anonymized. The 112 vortical blood flow in the MPA was assessed using a research software package (4D Flow, 113 Siemens Healthineers AG, Erlangen, Germany) in a randomized order. The datasets were 114 pre-processed by applying background phase correction following cropping of spatially 115 aliased structure if needed. The presence of pathological vortical blood flow was identified 116 using multi-planar reconstructed 3-dimensional vector fields, see Figure 1. Vortex duration 117 was defined as the percentage of the cardiac phases where vortical blood flow could be 118 identified (12). Subsequently, mPAP was calculated using a previously determined empirical 119 formula (9):

$$mPAP_{(CMR)}(mmHg) = \frac{Vortex \, duration \, (\%) + 25.44}{1.59} \tag{7}$$

The 4D flow analysis was performed for the first cohort by two independent readers (PB and a subset by GA), and for the second cohort by a single reader (GA). Analysis was consistently performed interchangeably on both CS-M2D and CS-4D datasets in a randomized fashion. Intra- and interobserver variability was assessed by selecting n=20 patients in the first cohort for which multiple readings were performed.

# 126 Statistical analysis

127	Continuous variables were reported as mean $\pm$ standard deviation (SD) for normally
128	distributed variables, while non-normally distributed variables were reported as median and
129	interquartile range. Categorical variables were reported as frequencies and percentages. To
130	quantify differences between CS-M2D and CS-4D measurements, two-tailed paired Student's
131	t-test was employed. Linear regression and Bland-Altman analysis were used to assess
132	correlations and biases. Further, to quantify agreements between identified frames containing
133	pathological MPA vortices, the Jaccard similarity coefficient was calculated as the mean of
134	the index derived for absence, and presence of pathological MPA vortices, respectively.
135	Intra- and interobserver variability was evaluated by means of Bland-Altman statistics,
136	calculating mean biases with standard deviations, along with the Jaccard similarity coefficient
137	as per above.
138	Statistical testing was performed using SPSS version 27 (IBM Corp., Armonk, NY, USA). A
139	significance level of p<0.05 was utilized for all analyses.

140

#### 142 **Results**

- 143 Of the 55 prospectively included patients, 10 were excluded from analysis owing to the
- 144 occurrence of arrhythmia during acquisition (n=4, affecting both CS-M2D and CS-4D),
- 145 unrecoverable phase aliasing (n=2, affecting both CS-M2D and CS-4D), aborted ECG
- 146 triggering (n=3, affecting CS-4D imaging), or post-scan reconstruction errors (n=1, affecting
- 147 CS-4D). Excluded acquisition were equally distributed between the two utilized scanners
- 148 (n=5 excluded from the Aera, n=5 excluded from the Sola). Demographics and CMR
- 149 characteristics for the remaining 45 patients are summarized in **Table 2**.

# 150 Diagnostic differentiation of pulmonary hypertension

- 151 Pulmonary hypertension (PH) defined as an estimated mPAP ≥20 mmHg was identified in
- 152 25/45 (56%) subjects by CS-M2D and 20/45 (44%) subjects by CS-4D. In 86% of the cases,
- both CS-M2D and CS-4D provided consistent classifications. Discrepancies arose in six
- 154 subjects: five patients were classified with PH by CS-M2D, and one patient was classified
- 155 with PH by CS-4D, see Table 3. For the subgroup who underwent reference standard
- 156 invasive RHC (n=20), CS-M2D and RHC classifications agreed perfectly, confirming PH in
- 157 18 patients and ruling it out in two (mPAP <20 mmHg). Conversely, CS-4D exhibited
- 158 discrepancies in three cases, two false positives and one false negative. An overview of the
- 159 classification by CS-M2D vs CS-4D is given in **Figure 2**.

# 160 Quantification of mPAP

- 161 The time between RHC and CMR was 61 [40-142] days. Both CS-M2D and CS-4D
- approaches demonstrated excellent agreement for non-invasive estimation of mPAP with a
- high level of agreement ( $R^2=0.93$ , p<0.001) and low bias ( $0.0\pm2.7$  mmHg, Figure 3). There
- 164 was no difference between estimated mPAP by CS-M2D and CS-4D in the overall cohort

- 165 (24.3 $\pm$ 9.9 vs. 23.7 $\pm$ 9.2 mmHg, p = 0.15). The Jaccard similarity coefficient was 0.79 between
- 166 mPAP estimated by CS-M2D and CS-4D across the entire cohort.

#### 167 Comparison between estimated mPAP by CMR and RHC

- 168 Strong correlations were observed between mPAP measured by RHC and estimated by CS-
- 169 M2D (R<sup>2</sup>=0.92, p < 0.001), with an effective absence of any bias and good precision (0.6±3.1
- 170 mmHg, Figure 4). CS-4D also exhibited strong correlation with RHC ( $R^2=0.86$ , p<0.001)
- and a similarly low mean bias and good precision (1.1±4.6 mmHg, Figure 4). Estimated
- 172 mPAP did not differ between CS-M2D, CS-4D, and RHC (CS-M2D vs CS-4D: p=0.98; CS-
- 173 M2D vs RHC: p=0.80; CS-4D vs RHC: p=0.59).

# 174 *Reproducibility analysis*

- 175 From the intraobserver variability analysis, strong agreement was observed for both repeated
- 176 CS-M2D (mean bias: 0.8±4.4 mmHg; Jaccard similarity index: 0.78) and CS-4D (mean bias:
- 177 0.8±2.0 mmHg; Jaccard similarity index: 0.79) readings, respectively. For the interobserver
- 178 variability analysis, similar negligible bias was observed although with higher variation for
- both repeat CS-M2D (mean bias: 0.3±9.0 mmHg; Jaccard similarity index: 0.54) and CS-4D
- 180 (mean bias: 1.6±7.7 mmHg; Jaccard similarity index: 0.55) readings, respectively. An
- 181 overview of the reproducibility readings is provided in **Figure 5**.

# 182 Scan time

183 With estimates taken from a subgroup of 8 patients, average scan duration for CS-M2D and

184 CS-4D were  $175\pm36$  s and  $135\pm34$  s, respectively.

- 185
- 186

### 187 **Discussion**

The main finding of the current study is that both CS-M2D and CS-4D imaging approaches using CMR yield interchangeable results that both represent accurate estimations of mPAP when validated against invasive RHC. These results further highlight the potential of CMR as a non-invasive alternative for diagnosis of pulmonary hypertension; in-line with previous findings in literature (9, 16, 17).

193 In previous studies, CMR-based estimation of mPAP has been performed using the M2D

approach without CS acceleration (9, 10, 12). Whilst a recent study showed that CS

195 acceleration had non-inferior performance (16), the current study represents the first head-to-

196 head comparison between CS-M2D and CS-4D, and the first comparison of these techniques

197 to invasive RHC. Here, we aimed to replicate the previously published CS-M2D sequence,

198 with the CS-4D representing a state-of-the-art comparator. As highlighted in **Table 1**, this

199 resulted in a number of differences relating to effective voxel size, temporal resolution, and

200 overall acquisition time. Specifically, CS-M2D used a voxel size of 1.8x1.8x6.0 mm<sup>3</sup> as

201 compared to CS-4D at 2.0x2.5x2.5 mm<sup>3</sup>. As such, flow coverage by CS-4D is almost twice as

202 dense as compared to CS-M2D in the slice direction, with only minor differences in in-plane

203 resolution. CS-4D would thus have the theoretical ability to quantify finer flow details

204 compared to CS-M2D. Furthermore, there are slight differences in temporal resolution in the

205 utilized acquisition settings, and the nature of CS-M2D imaging involves spatially contiguous

206 but temporally disparate slice acquisitions. This presents theoretical challenges for the CS-

207 M2D approach, particularly in transient or complex anatomies and flows. However, the

208 current study highlights the effectively equivalent capabilities of CS-4D and CS-M2D for

209 non-invasive estimation of mPAP despite these theoretical differences and challenges.

210 Early detection of PH is associated with improved prognosis (18), however, the majority of 211 PH patient diagnosed present at an advance stage (NYHA class III and IV), leaving early 212 detection a remaining and urgent clinical challenge (19). Early detection is typically 213 attempted using echocardiography. However, it has been shown that identifying PH by 4D 214 flow analysis by CMR has twice the diagnostic yield compared to echocardiography (20), and 215 this increased diagnostic performance has been confirmed compared to RHC (17). 216 Furthermore, identifying PH is a central component of assessing diastolic dysfunction, which 217 plays a central role in the diagnosis and therapeutic evaluation in heart failure with preserved 218 ejection fraction (HFpEF). Indeed, estimation of mPAP by 4D flow analysis can be used to 219 perform grading of diastolic dysfunction by CMR, and this has shown excellent agreement 220 compared to echocardiography (21). These described clinical applications of 4D flow 221 analysis by CMR to date have all used M2D acquisition without CS acceleration, and the 222 results of the current study now provide the field with important confidence to use CS to 223 drastically reduce acquisition time from an average of 9 minutes to under 3 minutes, which 224 provides valuable improvements in clinical throughput capacity for CMR imaging facilities. 225 Insights into clinical utility were also provided by the reproducibility study. As presented in 226 Figure 5, negligible bias was reported in an intraobserver setting, and in the interobserver 227 setting observer bias was kept below 1.6 mmHg across all subjects and acquisition sequences, 228 respectively. Nevertheless, increased variance was observed in the interobserver setting; a 229 finding aligning with the nature of multiple observers, but still highlighting challenges 230 associated with manual image interpretation. Recent developments on semi-automatic or 231 even fully automatic vortex detection in the setting of pulmonary flow imaging has shown 232 high clinical potential (22, 23), herein offering a promising path towards mitigating reader 233 bias and maintaining accurate estimation of performance.

234 The current study has some limitations that need to be acknowledged. First, a relatively small 235 number of patients were included, in particular in the subgroup that underwent RHC. As 236 such, further validation in larger cohorts could be of benefit, and would aid in the 237 understanding of how the current results can generalize into other centers or across larger and 238 differently composed populations. That said, it has already been shown that estimating mPAP 239 with the M2D approach is excellently accurate and robust across all subtypes of PH (9). 240 Second, pathological vortex detection as performed in the current study is currently a 241 manually performed method, which is not only time consuming, but also leaves room for 242 observer variations as highlighted in the reproducibility study. As noted above, efforts to 243 reduce observer dependence have recently been presented through incorporation of semi-244 automatic or fully automatic vortex detection algorithms (22, 23). A such, the current results 245 provide the basis and confidence for understanding accuracy and sequence performance, from 246 which further optimization can be envisioned.

# 247 Conclusion

248 CS-accelerated CMR 4D flow analysis provides means for accurate and clinically feasible

non-invasive assessment of mPAP using either CS-M2D or CS-4D approaches, opening for a
 more accessible way of diagnosing PH compared to invasive catheterization.

# 252 List of abbreviations

- 253 4D-Four-dimensional
- 254 CMR cardiovascular magnetic resonance
- 255 mPAP mean pulmonary artery pressure
- 256 CS compressed sensing
- 257 CS-M2D compressed sensing multiple two-dimensional (flow sequence)
- 258 CS-4D compressed sensing time-resolved three-dimensional (flow sequence)
- 259 RHC right heart catheterization
- 260 bSSFP balanced steady-state free precession
- 261 MPA main pulmonary artery
- 262 RV right ventricle
- 263 TAPSE tricuspid annular plane excursion

# 265 **Declarations**

#### 266 *Ethics approval and consent to participate*

- 267 All subjects provided written informed consent, and the study was approved by the Swedish
- 268 Ethical Review Authority (DNR: 2015/2106-31/1).
- 269 Consent for publication
- 270 Not applicable.
- 271 Availability of data and materials
- 272 The datasets used and/or analysed during the current study are available from the
- 273 corresponding author on reasonable request.

# 274 Competing interests

- 275 D.G., N.J. and F.T. are employees of Siemens Healthineers. G.A., P.B., J.C., A.F., P.S., A.S.,
- 276 M.U., and D.M. are all either employed by or affiliated with Karolinska University Hospital,
- 277 which has an institutional research and development agreement regarding cardiovascular
- 278 magnetic resonance with Siemens Healthineers.

# 279 Funding

- 280 This work was funded in part by the European Union (ERC, MultiPRESS, 101075494).
- 281 Views and opinions expressed are those of the authors and do not reflect those of the
- 282 European Union or the European Research Council Executive Agency. Funding was also
- 283 provided in part by New South Wales Health, Heart Research Australia, University of

284 Sydney.

# 285 Author's contributions

- 286 D.M. and M.U. conceived of the study, with G.A., P.B., M.U. and D.M. involved in study
- design, patient recruitment, and primary image and statistical analysis. D.G., N.J., and F.T.
- were involved in sequence acquisition design, with A.F., A.S., and J.C. leading local
- implementation and guidance on image acquisition and analysis. D.M., M.U., A.S., and P.S.
- supervised P.B and G.A., taking part in analysis and preliminary data assessment. All authors
- 291 were involved in manuscript drafting, and all authors approved of the final manuscript.

# 292 Acknowledgement

- Not applicable.
- 294
- 295

#### 296 References

297 Markl M, Chan FP, Alley MT, Wedding KL, Draney MT, Elkins CJ, et al. Time-1. 298 resolved three-dimensional phase-contrast MRI. J Magn Reson Imaging. 2003;17(4):499-299 506. 300 Barker AJ, Staehle F, Bock J, Jung BA, Markl M. Analysis of complex cardiovascular 2. 301 flow with three-component acceleration-encoded MRI. Magn Reson Med. 2012;67(1):50-61. 302 3. Goldberg A, Jha S. Phase-contrast MRI and applications in congenital heart disease. 303 Clin Radiol. 2012;67(5):399-410. 304 Markl M, Kilner PJ, Ebbers T. Comprehensive 4D velocity mapping of the heart and 4. 305 great vessels by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13(1):7. 306 Stankovic Z, Allen BD, Garcia J, Jarvis KB, Markl M. 4D flow imaging with MRI. 5. 307 Cardiovasc Diagn Ther. 2014;4(2):173-92. 308 Nordmeyer S, Riesenkampff E, Messroghli D, Kropf S, Nordmeyer J, Berger F, et al. 6. 309 Four-dimensional velocity-encoded magnetic resonance imaging improves blood flow 310 quantification in patients with complex accelerated flow. J Magn Reson Imaging. 311 2013;37(1):208-16. 312 Markl M, Draney MT, Hope MD, Levin JM, Chan FP, Alley MT, et al. Time-7. 313 resolved 3-dimensional velocity mapping in the thoracic aorta: visualization of 3-directional 314 blood flow patterns in healthy volunteers and patients. J Comput Assist Tomogr. 315 2004;28(4):459-68. 316 Bächler P, Pinochet N, Sotelo J, Crelier G, Irarrazaval P, Tejos C, et al. Assessment of 8. 317 normal flow patterns in the pulmonary circulation by using 4D magnetic resonance velocity 318 mapping. Magn Reson Imaging. 2013;31(2):178-88. 319 Reiter G, Reiter U, Kovacs G, Olschewski H, Fuchsjäger M. Blood flow vortices 9. 320 along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary 321 hypertension. Radiology. 2015;275(1):71-9. 322 Reiter G, Reiter U, Kovacs G, Kainz B, Schmidt K, Maier R, et al. Magnetic 10. 323 Resonance–Derived 3-Dimensional Blood Flow Patterns in the Main Pulmonary Artery as a 324 Marker of Pulmonary Hypertension and a Measure of Elevated Mean Pulmonary Arterial 325 Pressure. Circ Cardiovasc Imaging. 2008;1(1):23-30. 326 Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. 11. 327 Pulmonary Hypertension as a Prognostic Indicator at the Initial Evaluation in Idiopathic 328 Pulmonary Fibrosis. Respiration. 2012;85(6):456-63. 329 Reiter U, Reiter G, Kovacs G, Stalder AF, Gulsun MA, Greiser A, et al. Evaluation of 12. 330 elevated mean pulmonary arterial pressure based on magnetic resonance 4D velocity 331 mapping: comparison of visualization techniques. PLoS One. 2013;8(12):e82212. 332 Bissell MM, Raimondi F, Ait Ali L, Allen BD, Barker AJ, Bolger A, et al. 4D Flow 13. 333 cardiovascular magnetic resonance consensus statement: 2023 update. J Cardiovasc Magn 334 Reson. 2023;25(1):40. 335 Ma LE, Markl M, Chow K, Huh H, Forman C, Vali A, et al. Aortic 4D flow MRI in 2 14. 336 minutes using compressed sensing, respiratory controlled adaptive k-space reordering, and 337 inline reconstruction. Magn Reson Med. 2019;81(6):3675-90. 338 15. Bollache E, Barker AJ, Dolan RS, Carr JC, van Ooij P, Ahmadian R, et al. k-t 339 accelerated aortic 4D flow MRI in under two minutes: Feasibility and impact of resolution, k-340 space sampling patterns, and respiratory navigator gating on hemodynamic measurements. 341 Magn Reson Med. 2018;79(1):195-207. 342 Abdula G, Ramos JG, Marlevi D, Fyrdahl A, Engblom H, Sörensson P, et al. Non-16. invasive estimation of mean pulmonary artery pressure by cardiovascular magnetic resonance 343

- 344 in under 2 min scan time. European Heart Journal - Imaging Methods and Practice. 345 2023;1(1).
- 346 Ramos JG, Wieslander B, Fyrdahl A, Reiter G, Reiter U, Jin N, et al. Pulmonary 17.
- 347 Hypertension by Catheterization Is More Accurately Detected by Cardiovascular Magnetic
- 348 Resonance 4D-Flow Than Echocardiography. JACC Cardiovasc Imaging. 2023;16(4):558-9.
- 349 Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial 18. 350 hypertension. Nat Rev Cardiol. 2015;12(3):143-55.
- 351 Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al. Changing 19.
- 352 demographics, epidemiology, and survival of incident pulmonary arterial hypertension:
- 353 results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J
- 354 Respir Crit Care Med. 2012;186(8):790-6.
- 355 Ramos JG, Fyrdahl A, Wieslander B, Reiter G, Reiter U, Jin N, et al. Cardiovascular 20.
- 356 magnetic resonance 4D flow analysis has a higher diagnostic yield than Doppler
- 357 echocardiography for detecting increased pulmonary artery pressure. BMC Med Imaging. 358 2020;20(1):28.
- 359 Ramos JG, Wieslander B, Fyrdahl A, Reiter G, Reiter U, Jin N, et al. Pulmonary 21.
- 360 Hypertension by Catheterization Is More Accurately Detected by Cardiovascular Magnetic 361 Resonance 4D-Flow Than Echocardiography. JACC Cardiovasc Imaging.0(0).
- 362 Kräuter C, Reiter U, Kovacs G, Reiter C, Masana M, Olschewski H, et al. Automated 22. 363 vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI.
- 364 Magn Reson Imaging. 2022;88:132-41.
- 365 23. Sabry M, Lamata P, Sigfridsson A, Keramati H, Fyrdahl A, Ugander M, et al., editors. 366 Vortex Duration Time to Infer Pulmonary Hypertension: In-Silico Emulation
- and Dependence on Quantification Technique2023; Cham: Springer Nature Switzerland. 367

# 370 Figures

- 371
- 372



373 374

**Figure 1**. Vortical blood flow visualized in the main pulmonary artery in an oblique sagittal

376 view for a patient with pulmonary hypertension (mPAP 35 mmHg by right heart

377 catheterization), using CS-M2D (top row) and CS-4D (bottom row) across four representative

time frames out of total 20 cardiac phases. The visualization is using multiplanar reformatted

379 3D velocity vector arrows color-coded for velocity. White arrow indicates a vortex.

	Frequency of patients in each group comparing CS-M2D to CS-4D				
CS-M2D CS-4D		CS-M2D	Noi	Increased PA pressure	
		)	No observable vortex	Estimated mPAP <20 mmHg	Estimated mPAP ≥ 20 mmHg
	mal	No observable vortex	15 (33 %)	0	2 (4%)
	Nor	Estimated mPAP <20 mmHg	2 (4 %)	2 (4 %)	3 (7 %)
	Increased PA pressure	Estimated mPAP ≥ 20 mmHg	0	1 (2 %)	20 (44 %)

384

Figure 2. Distribution of pulmonary artery pressure diagnosis, comparing classification by

PA vortex duration detected by CS-M2D and CS-4D. 





Figure 3. Linear regression (a) and (b) Bland-Altman Plots of the estimated mean pulmonary

arterial pressures (mPAP) from vortex duration determined by CS-M2P and CS-4D. 





400 Figure 4. Linear regression and Bland-Altman Plots of mean pulmonary arterial pressures (mPAP) measured at right heart catheterization (RHC) and estimated mPAP by CS-M2D 401 402 method (a-b) and estimated mPAP by CS-4D (c-d).

- 403
- 404



Figure 5. Bland-Altman Plots of mean pulmonary arterial pressures (mPAP) estimated by
CS-M2D and by CS-4D, showing intra- (a-b) and interobserver (c-d) variability across a
randomly selected subset of n=20 patients.

- 409
- 410

#### Tables

413

Parameters	CS-M2D		C	CS-4D	
	Aera 1.5T	Sola 1.5T	Aera 1.5T	Sola 1.5T	
Field of view (mm)	340	340	320	320	
Voxel size (mm <sup>3</sup> )	1.8 x 1.8 x 6.0	1.8 x 1.8 x 6.0	2.0 x 2.5 x 2.5	2.0 x 2.5 x 2.5	
Number of Slices	10	10	30	30	
Velocity encoding (VENC, cm/s)	90	90	90	90	
Bandwidth (Hz/pixel)	449	449	558	558	
Flip angle (°)	15	15	15	15	
Temporal resolution (ms)	75.24	70.0	58.68	61.1	
Reconstructed time frames, n	20	20	20	20	
Echo time (ms)	4.10	3.61	2.55	3.0	
Repetition time (ms)	6.27	5.83	4.89	5.09	
Slice coverage (mm)	60	60	60	60	
Acceleration factor	7.7	8.8	6.0	7.6	
Respiratory navigator type	-	-	Pencil beam	Cross-pair	

#### 417 418

Table 2. Patient demographics and clinical character	ristics
Number of patients, n	45
Age, years	$55.6\pm19.3$
Female, n (%)	26 (58)
BMI, kg/m <sup>2</sup>	$24.8 \pm 5.2$
BSA, m <sup>2</sup>	$1.9 \pm 0.2$
Heart rate, beats per minute	$71 \pm 13$
LV EDV, ml	145 [112-191]
LV EDV index ml/m <sup>2</sup>	80 [66-90]
LV ESV, ml	59 [39-73]
LV ESV index, ml/m <sup>2</sup>	31 [24-42]
LV SV, ml	84 [68-103]
LV SV index ml/m <sup>2</sup>	45 [38-53]
LV EF, %	60 [54-64]
LV mass, g	115 [87-144]
LV mass index, g/m <sup>2</sup>	60 [50-70]
RVDd, mm	46 [46-51]
TAPSE, mm	24 [21-27]

BMI = body mass index; BSA = body surface area; LV = left ventricular; EDV = end diastolic volume; ESV = end systolic volume; SV = stroke volume; RVDd = right ventricular dimension at end-diastole; TAPSE = tricuspid annular plane excursion.

419

# 421

Table 3. Identification of PH by CS-M2D vs CS-4D: mPAP > 20 mmHg					
	CS-M2D				
CS-4D	Non-PH	РН	Total		
Non-PH	19 (42%)	5 (11%)	24		
PH	1 (2%)	20 (44%)	21		
Total	20 (44%)	25 (56%)	45		

PH = pulmonary hypertension